Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1 11Phase 3 4Phase 1/2 3Phase NA 1Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4Neoplasm Metastasis 1Lung Neoplasms 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Interventional × dacomitinib × Clear all
NCT06486142 2026-05-14

ERIS

Region Skane

Phase 3 Recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Pfizer

Phase 3 Completed
452 enrolled 35 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01000025 2023-08-22

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

Canadian Cancer Trials Group

Phase 3 Completed
720 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01360554 2017-05-24

ARCHER 1009

Pfizer

Phase 3 Completed
878 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡